BALTIMORE, Oct. 20 /PRNewswire/ -- Celsis International is pleased to announce that the United States Patent and Trademark Office today issued U.S. Patent No. 7,604,929 to Celsis In Vitro Technologies (Celsis IVT). This patent generally covers processes by which the company creates its unique LiverPool(TM) products for drug discovery research. The pooling process combines primary cells from multiple donors to create large lots with targeted activity levels. The resulting LiverPool product is flexible, customizable and repeatable, enabling scientists to run multiple studies on various compounds or NCEs anywhere in the world, and at any time, which speeds up decision making and reduces the time and cost of drug research.
“Our LiverPool product is a great example of Celsis IVT’s pioneering work in developing ADME-Tox products that meet the research needs of our customers, while helping to take costs out of the drug discovery process,” said Judy Madden, vice president of strategic development for Celsis. “We’re proud that the US Patent Office has recognized our continued innovation and awarded us this patent.”
Celsis IVT has been producing LiverPool products for more than five years and they have been incorporated into the standard research protocols of major pharmaceutical companies around the world. Research conducted with LiverPool has documented its efficacy as a research tool in numerous ADME-Tox assays, including metabolic stability and clearance studies. Scientific posters and LiverPool product information are available online at www.celsis.com/liverpool.
About Celsis IVT
Celsis IVT is the premier world provider of specialized in vitro products for the study of metabolism, drug-drug interactions and toxicity in drug discovery and development. Since 1990, pharmaceutical and biotechnology companies have relied on Baltimore-based Celsis IVT for quality in vitro products for lead optimization. Celsis IVT products deliver faster time to results, enabling more productive and cost-effective research. Celsis IVT’s patented LiverPool products, cryo-plateable hepatocytes (the world’s largest inventory) and other ADMET research tools are available worldwide. Visit www.celsis.com/ivt for more information.
About Celsis International
Chicago-based Celsis International is a leading global provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries. Each Celsis division delivers substantial time and cost savings to its customers while ensuring product quality and safety for consumers. Celsis’ extensive client base includes leading pharmaceutical and consumer products companies, including all 25 of the top 25 pharmaceutical companies worldwide. Visit www.celsis.com.
SOURCE Celsis International
CONTACT: Cindy Lieberman - Corporate Marketing of Celsis International,
+1-312-476-1200, clieberman@celsis.com; or Andrea Davis of Outlook
Marketing Services, Inc., +1-312-873-3421, andrea@outlookmarketingsrv.com,
for Celsis International
Web site: http://www.celsis.com/
